Trial Profile
"MIRO" (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL_MIRO
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 02 Aug 2021 Planned End Date changed from 1 Oct 2021 to 1 Feb 2022.